Gilead Sciences (GILD) Rating Reiterated by Oppenheimer
Gilead Sciences (NASDAQ:GILD)‘s stock had its “hold” rating restated by equities researchers at Oppenheimer in a report released on Wednesday.
A number of other analysts have also weighed in on GILD. Zacks Investment Research upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $86.00 price objective on the stock in a research note on Wednesday, July 18th. Robert W. Baird lowered shares of Gilead Sciences from an “outperform” rating to a “neutral” rating and set a $79.00 price target on the stock. in a research report on Thursday, July 26th. Wells Fargo & Co raised their price target on shares of Gilead Sciences from $89.00 to $95.00 and gave the company an “outperform” rating in a research report on Thursday, July 26th. Morgan Stanley raised their price target on shares of Gilead Sciences from $81.00 to $85.00 and gave the company an “equal weight” rating in a research report on Thursday, July 26th. Finally, Mizuho set a $94.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Tuesday, July 31st. Eleven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $88.63.
NASDAQ:GILD opened at $69.78 on Wednesday. The firm has a market capitalization of $91.19 billion, a PE ratio of 8.15, a price-to-earnings-growth ratio of -2.73 and a beta of 1.01. Gilead Sciences has a 1-year low of $64.27 and a 1-year high of $89.54. The company has a current ratio of 3.45, a quick ratio of 3.37 and a debt-to-equity ratio of 1.09.
In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the stock in a transaction on Monday, October 1st. The shares were sold at an average price of $78.04, for a total transaction of $3,902,000.00. Following the transaction, the director now directly owns 3,067,762 shares of the company’s stock, valued at $239,408,146.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have sold 150,000 shares of company stock worth $11,087,500. Insiders own 1.16% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the business. Sumitomo Mitsui Financial Group Inc. purchased a new position in Gilead Sciences during the third quarter valued at $100,000. Reilly Financial Advisors LLC lifted its holdings in Gilead Sciences by 98.3% during the third quarter. Reilly Financial Advisors LLC now owns 1,420 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 704 shares in the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new position in Gilead Sciences during the second quarter valued at $132,000. Brand Asset Management Group Inc. purchased a new position in Gilead Sciences during the second quarter valued at $139,000. Finally, TRUE Private Wealth Advisors purchased a new position in Gilead Sciences during the third quarter valued at $174,000. 78.18% of the stock is currently owned by institutional investors and hedge funds.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Featured Story: No Load Funds
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.